Safety and protocol notice: This is a detailed learning resource for emergency-medicine and ANC students in Uganda. Medication doses and testing schedules must be checked against the current Uganda Ministry of Health guideline, local formulary, gestational age, allergies, HIV/TB/malaria status and senior clinical advice. A woman with shock, heavy bleeding, convulsion, severe hypertension, sepsis, severe pain, breathlessness or reduced fetal movement needs urgent triage and referral; do not delay life-saving care for routine tests.
Scope: This post integrates the supplied teaching presentations on antenatal examination, investigations, prophylactic medications and antenatal danger signs with Uganda’s Safe Mama/goal-oriented ANC approach and WHO maternal–fetal assessment principles. It explains what to order, why it matters, when to repeat it, how to act on an abnormal result, and how to teach a pregnant woman to seek help early.
Learning objectives
- Separate screening, diagnostic and monitoring investigations in pregnancy.
- Build a practical Uganda ANC investigation package for the booking, second-trimester and third-trimester contacts.
- Interpret the most important maternal and fetal results and link each abnormality to a safe next action.
- Explain prophylactic medicines, vaccines and preventive interventions with purpose, timing, dose principles, contraindications and counselling.
- Recognise pregnancy danger signs, provide immediate first aid and arrange appropriate referral.
1. The clinical sequence when a woman presents
- Rapid triage: ABCDE, mental state, bleeding, pain, temperature, BP, pulse, respiratory rate, oxygen saturation when available, urine output and fetal status.
- Stabilise first: resuscitate shock, control seizures, manage severe hypertension, treat hypoglycaemia, give oxygen when indicated, start sepsis or haemorrhage pathways and call senior help.
- Focused history and examination: gestational age, symptoms, obstetric risk, medications/allergies, examination and fetal assessment.
- Choose tests that answer a question: do not order panels blindly; label specimens with gestational age and urgent clinical details.
- Act and communicate: explain results, document, treat or refer, give danger-sign advice and arrange a follow-up date.
Core principle: A normal test never overrides an unstable clinical picture. A woman with suspected ectopic pregnancy, abruption, sepsis or eclampsia needs emergency management even while samples are being collected.
2. Investigations: screening versus diagnosis
| Type | Purpose | Examples in pregnancy |
|---|---|---|
| Screening | Finds people at increased probability before symptoms or complications. | HIV, syphilis, hepatitis B, anaemia, blood group/RhD, urine protein, ultrasound dating/anomaly scan, risk-based diabetes testing. |
| Diagnostic | Confirms or excludes a suspected condition. | Urine culture for UTI, confirmatory HIV test, malaria test, ultrasound for ectopic/placenta, glucose tolerance test, diagnostic amniocentesis or chorionic-villus sampling when indicated. |
| Monitoring | Tracks disease, treatment response or fetal wellbeing over time. | Serial Hb, BP/proteinuria, HIV viral load, blood glucose, fetal growth/SFH, Doppler, NST/CTG and biophysical profile. |
3. Booking/first-contact investigations (ideally by 12 weeks)
| Investigation | What it detects and why it matters | What to do with an abnormal result |
|---|---|---|
| Haemoglobin/CBC | Anaemia, thrombocytopenia, infection clues and baseline before delivery. Review MCV/MCH for iron deficiency versus haemoglobinopathy. | Assess severity and symptoms, check diet/adherence, treat iron deficiency, investigate bleeding/malaria/haemoglobinopathy and refer severe or symptomatic anaemia. |
| ABO and RhD group | Plans transfusion and identifies an RhD-negative woman at risk of alloimmunisation. | Document clearly. If RhD negative, arrange antibody screen and anti-D plan according to Uganda protocol after sensitising events and postpartum. |
| HIV test with consent | Enables immediate lifelong ART, prevention of mother-to-child transmission (eMTCT), partner support and infant prophylaxis. | Use the national serial testing algorithm; provide confidential counselling, start/continue ART promptly and link to viral-load monitoring and eMTCT services. Never disclose without consent. |
| Syphilis test (RPR/VDRL or rapid treponemal test) | Detects maternal infection that can cause miscarriage, stillbirth, congenital syphilis and neonatal disease. | Treat immediately with penicillin according to national protocol, test/treat partner(s), document titres when relevant and arrange follow-up; do not wait for symptoms. |
| Urine dipstick | Protein suggests hypertensive disease when combined with raised BP; glucose may suggest diabetes; leucocytes/nitrites suggest UTI. | Repeat clean-catch if contamination is likely. Protein plus hypertension/symptoms needs pre-eclampsia assessment; culture suspected UTI and treat safely. |
| Urine microscopy/culture | Detects asymptomatic bacteriuria and resistant organisms when indicated, especially with recurrent UTI, fever, dysuria, renal disease or high risk. | Send before antibiotics where this will not delay treatment; tailor antibiotic to culture and pregnancy safety; confirm cure in recurrent/complicated cases. |
| Hepatitis B surface antigen | Identifies maternal infection and the need for newborn vaccination/immunoprophylaxis and specialist linkage. | Confirm and stage where indicated, counsel on household/sexual prevention, plan delivery/newborn prophylaxis and follow national PMTCT/hepatitis pathway. |
| Malaria test (RDT or microscopy when indicated) | Malaria may present as fever, anaemia, hypoglycaemia, miscarriage, growth restriction or severe illness in Uganda. | Treat confirmed malaria immediately with gestation-appropriate regimen; assess severe disease, anaemia and fetal status. A negative RDT does not exclude another infection. |
| Blood glucose or HbA1c where available | Finds pre-existing diabetes or women needing formal gestational-diabetes testing; HbA1c is not a universal replacement for OGTT. | Use local criteria; arrange fasting glucose/OGTT when risk or symptoms indicate and refer abnormal results for diet, monitoring and treatment. |
| Ultrasound | Confirms intrauterine location/viability, number of fetuses, dating, anatomy, placenta and fluid; early ultrasound is most accurate for dating. | Urgent scan for pain/bleeding, uncertain dates, size-date discrepancy, reduced movement or suspected growth/placental problem. Document scan date and revised EDD. |
| Tuberculosis and other infection screening | Symptom screen and targeted tests for cough, fever, weight loss, contact, COVID/influenza or other local threats. | Use infection-control precautions, test and treat according to Uganda guidelines; assess contacts and nutrition. |
4. Repeat and trimester-specific investigations
Second trimester (13–28 weeks)
- Review all booking results and confirm that abnormal results were treated, documented and communicated.
- Repeat Hb around 26 weeks or earlier if anaemia symptoms/risk. Look for a falling trend, not only a single number.
- Repeat HIV and syphilis testing according to Uganda schedule and risk; offer retesting after a window period or new exposure.
- Urine protein and glucose, BP and SFH at every contact; send culture for symptoms or persistent dipstick abnormality.
- Glucose testing/OGTT at 24–28 weeks when risk factors, symptoms or local protocol indicate: previous gestational diabetes or macrosomia, obesity, strong family history, glycosuria, polyhydramnios or suspected large fetus.
- Ultrasound before 24 weeks when available for dating, fetal number, anatomy, placental site and cervical assessment where indicated.
- Malaria RDT/microscopy for fever or compatible symptoms; do not treat a negative test as “no illness” without considering other causes.
Third trimester (28 weeks to birth)
- Repeat Hb, HIV viral load/clinical monitoring and syphilis testing per national pathway; assess adherence and eMTCT plan.
- Continue BP, urine protein, weight, SFH, fetal heart rate, movement and presentation assessment at each contact.
- Ultrasound, growth scan, Doppler, CTG/NST or biophysical profile only when indicated by risk, abnormal SFH, reduced movements, hypertension, diabetes, bleeding or other clinical concern.
- Repeat blood group/antibody review and prepare a transfusion plan for RhD-negative or high-risk women.
- Before delivery, review haemorrhage risk, placenta location, malpresentation, anaesthetic concerns, HIV status/viral load, transport and referral facility.
5. Maternal investigations in more detail
5.1 Anaemia and haemoglobinopathy
Pregnancy causes haemodilution, but severe anaemia is not physiological. Correlate Hb with pallor, dyspnoea, tachycardia, syncope, diet, bleeding, malaria, worm infestation and sickle-cell history. A low MCV suggests iron deficiency or haemoglobinopathy; a normal/high MCV raises folate/B12 deficiency, liver disease or other causes. Severe or symptomatic anaemia, heart failure, ongoing bleeding or very low Hb requires urgent senior review, cross-match and possible admission.
5.2 Blood group, RhD and antibodies
ABO/RhD results are not merely paperwork. Record them on the ANC card and referral notes. An RhD-negative unsensitised woman needs a documented anti-D plan after vaginal bleeding, abdominal trauma, invasive procedures, miscarriage/termination, ectopic pregnancy, external cephalic version and birth according to national availability and dose schedule. If antibody screen is positive, refer for specialist assessment; anti-D does not treat established sensitisation.
5.3 HIV, syphilis and hepatitis B
- Use provider-initiated testing with consent, confidentiality, counselling and the national confirmatory algorithm.
- For HIV, the priority is immediate linkage to lifelong ART, viral-load monitoring, adherence support, safe delivery and newborn prophylaxis—not an obsolete single-dose regimen.
- For syphilis, treat the mother and partner promptly, document treatment dates and ensure the newborn is assessed.
- For hepatitis B, avoid stigma, plan newborn vaccination/immunoglobulin when indicated, and link the mother for monitoring and treatment assessment.
5.4 Urine and renal assessment
Proteinuria must be interpreted with BP, symptoms, infection and contamination. A single trace dipstick is not a diagnosis. Persistent protein, hypertension, oliguria, haematuria or renal disease warrants repeat testing, renal function/electrolytes and senior assessment. Fever/flank pain in pregnancy is pyelonephritis until proven otherwise and can progress rapidly to sepsis.
6. Fetal and placental assessment
| Tool | Use | Important cautions |
|---|---|---|
| Fetal movements | Ask about the woman’s established pattern and any reduction/absence. | There is no single universal kick number. Any clear reduction from normal needs same-day assessment; do not rely on home counting to delay care. |
| Fetal heart rate | Doppler/Pinard confirms fetal cardiac activity and provides a baseline. | Check maternal pulse simultaneously. Persistent <110 or >160 bpm requires urgent reassessment and escalation. |
| SFH and serial growth | Trend after about 20–24 weeks to screen for growth restriction or large-for-gestation. | Obesity, fibroids, multiple pregnancy, abnormal liquor and wrong dates reduce accuracy; abnormal trend requires ultrasound. |
| Ultrasound | Dating, viability, number, anatomy, placenta, fluid, growth and Doppler when indicated. | It is not a substitute for history, BP, examination or fetal movement assessment. |
| NST/CTG | Assesses fetal heart-rate response and uterine activity in selected high-risk or reduced-movement cases. | Interpret within gestational age and clinical context; a “reactive” tracing does not remove the need to investigate maternal danger signs. |
| Biophysical profile | Combines ultrasound activity, tone, breathing, movement and fluid with CTG when concern for compromise exists. | Requires trained interpretation and a plan for action if abnormal. |
| Doppler studies | Umbilical/uterine artery Doppler can support assessment of placental insufficiency and growth restriction. | Use for indicated pregnancies and refer abnormal results; do not use as a stand-alone reassurance test. |
7. Prophylactic medications and preventive interventions in Uganda
Prescribe only after checking gestation, allergy, comorbidity, interactions and the current Uganda formulary. Document dose, route, date, batch where required, counselling and next dose.
7.1 Iron and folic acid
- Routine prevention: provide iron equivalent to about 30–60 mg elemental iron daily plus folic acid 400 micrograms (0.4 mg) daily, according to the Uganda product/formulary. Continue through pregnancy and postpartum as directed.
- High-risk folate: women with a previous neural-tube-defect pregnancy, malabsorption, sickle-cell disease or medicines that interfere with folate may need 5 mg daily before conception and through the first 12 weeks—prescriber-directed.
- Counselling: nausea, constipation and dark stools are common; take with water, separate from tea/coffee, calcium and antacids when possible, and do not stop without discussing alternatives.
- Treatment versus prophylaxis: confirmed anaemia often needs a higher therapeutic elemental-iron dose and investigation; do not label treatment doses as routine prevention.
7.2 Calcium
Where dietary calcium intake is low or pre-eclampsia risk is high, calcium supplementation may be recommended (WHO commonly uses 1.5–2.0 g elemental calcium daily in divided doses). Check the Uganda protocol, renal disease, stone history and interaction with iron; separate calcium and iron doses to improve absorption.
7.3 Intermittent preventive treatment of malaria in pregnancy (IPTp-SP)
- In malaria-endemic Uganda, give sulfadoxine–pyrimethamine under directly observed therapy from the second trimester/after the first trimester (commonly from 13 weeks), at least one month apart at ANC contacts; Uganda programmes generally target a minimum of three doses, with more doses when eligible under current policy.
- The usual dose is three tablets of sulfadoxine 500 mg/pyrimethamine 25 mg each (total sulfadoxine 1,500 mg/pyrimethamine 75 mg) orally once per dose.
- Do not give in the first trimester, to a woman with a serious sulfonamide reaction, or together with cotrimoxazole prophylaxis; follow the current national malaria guideline for HIV-positive women and drug interactions.
- IPTp does not treat symptomatic malaria. A febrile woman needs a malaria test and prompt treatment with a gestation-appropriate regimen.
- Promote a long-lasting insecticidal net (LLIN) every night, correct use, repair/replacement and environmental measures.
7.4 Deworming
After the first trimester, a national programme may offer mebendazole (for example 500 mg once, or the local approved equivalent) when indicated. Check gestational age, anaemia, nutrition, local transmission and the current Uganda schedule. Combine with sanitation, footwear and safe food/water practices.
7.5 Tetanus–diphtheria (Td) vaccination
- Review previous documented doses and give Td according to Uganda’s schedule; an incompletely immunised woman needs a series rather than a single undocumented injection.
- Explain that vaccination protects both mother and newborn from tetanus. Use a separate syringe and record date, product and dose.
- Defer only for a true contraindication such as a previous severe allergic reaction to a component; minor illness is not usually a reason to miss vaccination.
7.6 Low-dose aspirin for selected pre-eclampsia risk
For women at high risk (for example previous early pre-eclampsia, chronic hypertension, renal disease, autoimmune disease, diabetes or multifetal pregnancy), a clinician may prescribe low-dose aspirin, commonly 75–150 mg nightly from 12–16 weeks until around 36 weeks. Confirm local protocol, bleeding risk, allergy, peptic disease and platelet status. It is not a universal ANC vitamin and must not be started without risk assessment.
7.7 Anti-D immunoglobulin
For an RhD-negative, non-sensitised woman, anti-D is used after sensitising events and/or routinely late in pregnancy where the programme provides it. Check antibody status, gestation, event, product concentration and local dose protocol. Give as soon as recommended after bleeding, trauma, invasive procedures, miscarriage, ectopic pregnancy, external cephalic version and delivery; document clearly.
7.8 HIV eMTCT, vaccines and other prevention
- Offer/continue combination ART for every person with HIV according to current Uganda national guidance; monitor viral load and adherence, plan delivery and newborn prophylaxis, and support safe infant-feeding counselling.
- Offer influenza, COVID-19 or other vaccines only according to current national policy and individual risk; avoid live vaccines unless a specialist guideline specifically permits them.
- Ensure adequate iodised salt/dietary micronutrients; avoid high-dose vitamin A supplements in pregnancy unless prescribed for a specific indication because excess retinoid activity is teratogenic.
- Use condoms for STI/HIV prevention when indicated, test/treat partners, and counsel on avoiding tobacco, alcohol and non-prescribed drugs.
8. Danger signs in pregnancy
Tell every pregnant woman and family: do not wait for the next ANC appointment if any danger sign occurs. Call the health worker, arrange the fastest safe transport and carry the ANC card. Do not travel alone when faint, bleeding, convulsing or severely unwell.
| Danger sign | Possible causes | First response and referral priority |
|---|---|---|
| Any vaginal bleeding | Ectopic/miscarriage, placenta praevia, abruption, preterm labour, cervical disease or uterine rupture. | Assess ABCDE, quantify blood loss, check shock and fetal status, establish IV access if significant, avoid digital examination until placenta praevia excluded, urgent obstetric referral. |
| Convulsion, loss of consciousness or severe confusion | Eclampsia, epilepsy, hypoglycaemia, infection, stroke or trauma. | Protect from injury, left lateral, airway/oxygen/glucose checks, magnesium sulphate for suspected eclampsia per protocol, urgent senior care. |
| Severe/persistent headache, blurred vision or flashing lights | Pre-eclampsia, cerebral disease, migraine or infection. | Measure BP immediately, check urine/protein, neurological signs and fetal status; severe BP/symptoms are emergency. |
| Severe abdominal pain or tender/rigid uterus | Abruption, ectopic, labour, uterine rupture, appendicitis, torsion, renal/GI disease. | ABCDE, analgesia appropriate to pregnancy, bloods/cross-match, ultrasound/senior review; do not dismiss as gas or round-ligament pain. |
| Fever, rigors or foul vaginal discharge | Malaria, UTI/pyelonephritis, chorioamnionitis, pneumonia, HIV/TB or other sepsis. | Sepsis assessment, cultures where feasible, antibiotics/antimalarial per protocol, fluids with caution and urgent referral. |
| Leak of clear/green/bloody fluid | Ruptured membranes, cord/fetal compromise or infection. | Note time/colour/odour, check FHR and temperature, avoid unnecessary digital exams, urgent assessment. |
| Reduced or absent fetal movements | Fetal hypoxia, growth restriction, oligohydramnios, anaemia or fetal death. | Same-day fetal heart/CTG/ultrasound assessment. Do not delay by eating, sleeping or relying on a home count. |
| Severe vomiting/unable to drink | Hyperemesis, infection, ketoacidosis or other disease. | Check dehydration, weight, urine ketones/electrolytes/glucose; give safe antiemetic/fluids and admit if severe. |
| Difficulty breathing, chest pain or coughing blood | PE, pulmonary oedema, pneumonia, asthma or severe anaemia. | ABCDE, oxygen if indicated, urgent assessment; do not massage a swollen leg or delay transfer. |
| Sudden swelling of face/hands, severe leg swelling or unilateral painful calf | Pre-eclampsia, DVT, cardiac/renal disease. | Check BP/urine and symptoms; urgent thromboembolism or hypertensive-disease assessment. |
| Regular painful contractions or pelvic pressure before term | Preterm labour, infection, cervical insufficiency or ruptured membranes. | Assess gestation, membranes, cervix only when safe, fetal status and arrange facility management. |
9. Immediate first aid and referral algorithm
- Call for help and assign roles: airway/monitoring, IV/bloods, medication, documentation, family communication and transport.
- Position: left lateral for late pregnancy, recovery position after seizure, upright for pulmonary oedema unless shock dictates otherwise.
- Monitor: BP, pulse, RR, SpO₂, temperature, mental state, urine output, bleeding and fetal heart.
- Access and samples: IV cannula(s), FBC/Hb, group/cross-match, glucose, renal/liver tests and targeted tests—but do not delay treatment.
- Treat the syndrome: haemorrhage, eclampsia, sepsis, malaria, hypoglycaemia, asthma or anaphylaxis according to the current emergency protocol.
- Refer early: phone the receiving facility, send a written referral with gestation, observations, examination, tests, medicines/doses/times and response, and use a trained escort where possible.
- Handover using SBAR: Situation, Background, Assessment, Recommendation; confirm that the receiving clinician accepted the patient.
10. Counselling after tests and prophylaxis
- Explain what each test is for, when and how results will return, and what an abnormal result means.
- Use teach-back: “Please tell me which symptoms would make you return today and where you would go.”
- Discuss adherence, side effects, missed doses, storage, drug interactions and what to do if vomiting follows a dose.
- Give a written next appointment, emergency contact, transport plan and instructions to bring the ANC card.
- Respect confidentiality and obtain permission before involving a partner or family member.
11. Documentation checklist
- Gestational age and EDD basis; booking versus follow-up contact.
- Maternal observations, weight/MUAC, urine and examination.
- Tests requested, specimen date, result, interpretation and action.
- Medicine/vaccine name, dose, route, date, batch where required, contraindication check and counselling.
- Fetal heart, movement, SFH, presentation/lie and ultrasound/CTG findings.
- Risk classification, referrals, return date, danger signs taught and patient understanding.
12. Worked cases
Case 1: positive syphilis screen
A 19-week patient has a reactive RPR. Do not wait for a later ANC contact. Confirm according to the testing algorithm, start the recommended penicillin regimen promptly, assess allergy, treat/notify partner(s), document doses, arrange follow-up and plan newborn evaluation. Explain that treatment prevents congenital disease and is not a judgement about her character.
Case 2: anaemia with fever in malaria-endemic area
A 28-week woman is pale, tachycardic and febrile with Hb 7 g/dL. Stabilise and assess severity, test for malaria and other infection, send blood group/cross-match, evaluate bleeding/nutrition/haemoglobinopathy, treat the confirmed cause and involve senior staff. Routine iron alone is insufficient for severe symptomatic anaemia.
Case 3: RhD-negative bleeding
A 30-week RhD-negative woman reports fresh bleeding after a fall. Assess mother and fetus, exclude abruption/placenta problems, obtain antibody status and arrange anti-D within the recommended window if not sensitised, documenting product and dose. Refer urgently if bleeding, pain, contractions or abnormal FHR occurs.
Quick self-test
- List the minimum routine booking tests in the Uganda ANC package.
- Why are blood group/RhD and antibody status clinically important?
- State the usual elemental-iron/folate prevention principle and one reason a higher folate dose may be prescribed.
- When should IPTp-SP begin, what is the usual tablet dose, and which common prophylactic medicine interaction must be avoided?
- Name five danger signs that require same-day emergency assessment.
- Why should digital vaginal examination be avoided in unexplained antepartum bleeding until placenta praevia is excluded?
Answers
- Hb/CBC, HIV, syphilis, ABO/RhD, urine protein/glucose with culture when indicated, hepatitis B, targeted malaria/glucose/TB testing and ultrasound where available.
- To plan transfusion, detect alloimmunisation and prevent RhD sensitisation/haemolytic disease.
- About 30–60 mg elemental iron plus 400 micrograms folic acid daily, according to local product; 5 mg folic acid may be used for previous neural-tube defect, malabsorption, sickle cell or folate-interfering medicines under clinician guidance.
- After the first trimester/around 13 weeks in endemic areas; three SP tablets (500/25 mg each) once under observation, repeated at least monthly as eligible; avoid cotrimoxazole or serious sulfonamide allergy and follow Uganda policy.
- Examples: bleeding, convulsion, severe headache/visual change, severe abdominal pain, fever/rigors, fluid leakage, reduced fetal movement, severe dyspnoea/chest pain, severe vomiting or preterm contractions.
- A digital examination can worsen bleeding in placenta praevia; ultrasound/senior assessment must come first.
Further study and source integration
- Supplied Slideshare: Antenatal examination, investigation and prophylactic medications
- Supplied Slideshare: Danger signs of antenatal pregnancy
- Safe Mama Uganda: Antenatal care resource
- Uganda Ministry of Health: Goal-oriented ANC protocol/job aid
- WHO recommendations on antenatal care
Take-home message: ANC investigations are useful only when linked to action. Screen early, repeat what the guideline requires, treat positive results promptly, document prophylaxis accurately and teach every woman the danger signs that should trigger immediate care.
